当前位置:首页 - 行情中心 - 信邦制药(002390) - 财务分析 - 利润表

信邦制药

(002390)

  

流通市值:69.73亿  总市值:74.06亿
流通股本:18.30亿   总股本:19.44亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入4,823,207,646.873,256,476,093.851,605,127,137.436,350,025,827.03
营业收入4,823,207,646.873,256,476,093.851,605,127,137.436,350,025,827.03
二、营业总成本4,470,734,285.093,032,948,961.521,535,323,707.216,015,573,903.85
营业成本3,860,569,975.612,621,581,755.191,314,183,651.875,133,065,370.34
税金及附加20,837,796.7113,319,215.386,876,674.1628,185,564.31
销售费用254,852,297.29173,661,310.7585,664,834.87393,367,953.27
管理费用308,012,852.43206,643,266.08116,726,561.7420,768,469.06
研发费用2,047,197.91,666,146.84691,393.551,207,144.17
财务费用24,414,165.1516,077,267.2811,180,591.0638,979,402.7
其中:利息费用32,365,164.3821,565,345.6213,837,692.0351,787,695.9
其中:利息收入8,585,611.755,961,018.612,857,593.1613,539,280.07
加:投资收益-788,943.67-2,033,937.674,566.2537,426,822.02
资产处置收益-55,861.83-43,051.54-37,882.51-4,520.24
信用减值损失(新)-16,734,942.66-16,742,002.74251,094.66-62,632,718.04
其他收益4,954,859.814,053,699.541,100,465.537,080,999.81
营业利润平衡项目0000
四、营业利润339,848,473.43208,761,839.9271,121,674.15316,322,506.73
加:营业外收入2,364,102.151,459,020.111,217,905.7111,103,041.72
减:营业外支出6,511,746.71,398,758.17150,047.9414,031,996.01
利润总额平衡项目0000
五、利润总额335,700,828.88208,822,101.8672,189,531.92313,393,552.44
减:所得税费用32,255,423.1117,224,732.359,541,011.2244,977,052.86
六、净利润303,445,405.77191,597,369.5162,648,520.7268,416,499.58
持续经营净利润303,445,405.77191,597,369.5162,648,520.7268,277,017.63
终止经营净利润---139,481.95
归属于母公司股东的净利润246,574,999.15156,021,447.2952,944,770.89224,479,086.87
少数股东损益56,870,406.6235,575,922.229,703,749.8143,937,412.71
(一)基本每股收益0.130.080.030.12
(二)稀释每股收益0.130.080.030.12
九、综合收益总额303,445,405.77191,597,369.5162,648,520.7268,416,499.58
归属于母公司股东的综合收益总额246,574,999.15156,021,447.2952,944,770.89224,479,086.87
归属于少数股东的综合收益总额56,870,406.6235,575,922.229,703,749.8143,937,412.71
公告日期2023-10-302023-08-292023-04-292023-04-18
审计意见(境内)标准无保留意见
TOP↑